Skip to main content

Olaparib in Patients with Pancreatic Cancer with BRCA1 / 2 Mutations: Results from the Targeted Agent and Profiling Utilization Registry Study

Publication ,  Conference
Ahn, ER; Rothe, M; Mangat, PK; Garrett-Mayer, E; Calfa, CJ; Alva, AS; Suhag, V; Alese, OB; Dotan, E; Hamid, O; Yang, ES; Marr, AS; Palmer, MC ...
Published in: JCO Precision Oncology
January 1, 2024

PURPOSETargeted Agent and Profiling Utilization Registry (TAPUR) is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and genomic alterations known to be drug targets. Results of a cohort of patients with advanced pancreatic cancer with BRCA1/2 mutations treated with olaparib are reported. METHODSEligible patients had advanced pancreatic cancer, measurable disease, Eastern Cooperative Oncology Group performance status 0-2, adequate organ function, and no standard treatment options available. Genomic testing was performed in Clinical Laboratory Improvement Amendments-certified, College of American Pathologists-accredited site selected laboratories. Simon's two-stage design was used with a primary end point of disease control (DC), defined as objective response (OR) or stable disease of at least 16 weeks duration (SD16+) according to RECIST v1.1. Secondary end points included OR, progression-free survival (PFS), overall survival (OS), duration of response, duration of stable disease, and safety.RESULTSThirty patients with BRCA1/2 mutations were enrolled from November 2016 to August 2019. The median number of reported previous therapies was 3 (range, 1-10). Two patients were not evaluable and excluded from efficacy analyses. Two patients with complete response, three with partial response and three with SD16+, were observed for DC and OR rates of 31% (90% CI, 18 to 40; P =.04) and 18% (95% CI, 6 to 37), respectively. The median PFS was 8 (95% CI, 8 to 15) weeks, and the median OS was 38 (95% CI, 21 to 65) weeks. Three patients had at least one drug-related grade 3 adverse event or serious adverse event of anemia, fever, or oral mucositis.CONCLUSIONOlaparib showed antitumor activity in patients with advanced pancreatic cancer with BRCA1/2 mutations extending findings of recent studies of olaparib in patients with this disease.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

JCO Precision Oncology

DOI

EISSN

2473-4284

Publication Date

January 1, 2024

Volume

8

Related Subject Headings

  • 3211 Oncology and carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Ahn, E. R., Rothe, M., Mangat, P. K., Garrett-Mayer, E., Calfa, C. J., Alva, A. S., … Schilsky, R. L. (2024). Olaparib in Patients with Pancreatic Cancer with BRCA1 / 2 Mutations: Results from the Targeted Agent and Profiling Utilization Registry Study. In JCO Precision Oncology (Vol. 8). https://doi.org/10.1200/PO.23.00240
Ahn, E. R., M. Rothe, P. K. Mangat, E. Garrett-Mayer, C. J. Calfa, A. S. Alva, V. Suhag, et al. “Olaparib in Patients with Pancreatic Cancer with BRCA1 / 2 Mutations: Results from the Targeted Agent and Profiling Utilization Registry Study.” In JCO Precision Oncology, Vol. 8, 2024. https://doi.org/10.1200/PO.23.00240.
Ahn ER, Rothe M, Mangat PK, Garrett-Mayer E, Calfa CJ, Alva AS, et al. Olaparib in Patients with Pancreatic Cancer with BRCA1 / 2 Mutations: Results from the Targeted Agent and Profiling Utilization Registry Study. In: JCO Precision Oncology. 2024.
Ahn, E. R., et al. “Olaparib in Patients with Pancreatic Cancer with BRCA1 / 2 Mutations: Results from the Targeted Agent and Profiling Utilization Registry Study.” JCO Precision Oncology, vol. 8, 2024. Scopus, doi:10.1200/PO.23.00240.
Ahn ER, Rothe M, Mangat PK, Garrett-Mayer E, Calfa CJ, Alva AS, Suhag V, Alese OB, Dotan E, Hamid O, Yang ES, Marr AS, Palmer MC, Thompson FL, Yost KJ, Gregory A, Grantham GN, Hinshaw DC, Halabi S, Schilsky RL. Olaparib in Patients with Pancreatic Cancer with BRCA1 / 2 Mutations: Results from the Targeted Agent and Profiling Utilization Registry Study. JCO Precision Oncology. 2024.

Published In

JCO Precision Oncology

DOI

EISSN

2473-4284

Publication Date

January 1, 2024

Volume

8

Related Subject Headings

  • 3211 Oncology and carcinogenesis